Skip to main content
PLOS One logoLink to PLOS One
. 2021 Mar 8;16(3):e0248073. doi: 10.1371/journal.pone.0248073

Carob pod polyphenols suppress the differentiation of adipocytes through posttranscriptional regulation of C/EBPβ

Kasumi Fujita 1, Toshio Norikura 2, Isao Matsui-Yuasa 1, Shigenori Kumazawa 3, Sari Honda 3, Takumi Sonoda 4, Akiko Kojima-Yuasa 1,*
Editor: Juan J Loor5
PMCID: PMC7939365  PMID: 33684156

Abstract

Obesity is a major risk factor for various chronic diseases such as diabetes, cardiovascular disease, and cancer; hence, there is an urgent need for an effective strategy to prevent this disorder. Currently, the anti-obesity effects of food ingredients are drawing attention. Therefore, we focused on carob, which has high antioxidant capacity and various physiological effects, and examined its anti-obesity effect. Carob is cultivated in the Mediterranean region, and its roasted powder is used as a substitute for cocoa powder. We investigated the effect of carob pod polyphenols (CPPs) on suppressing increases in adipose tissue weight and adipocyte hypertrophy in high fat diet-induced obesity model mice, and the mechanism by which CPPs inhibit the differentiation of 3T3-L1 preadipocytes into adipocytes in vitro. In an in vivo experimental system, we revealed that CPPs significantly suppressed the increase in adipose tissue weight and adipocyte hypertrophy. Moreover, in an in vitro experimental system, CPPs acted at the early stage of differentiation of 3T3-L1 preadipocytes and suppressed cell proliferation because of differentiation induction. They also suppressed the expression of transcription factors involved in adipocyte differentiation, thereby reducing triacylglycerol synthesis ability and triglycerol (TG) accumulation. Notably, CPPs regulated CCAAT/enhancer binding protein (C/EBP)β, which is expressed at the early stage of differentiation, at the posttranscriptional level. These results demonstrate that CPPs suppress the differentiation of adipocytes through the posttranscriptional regulation of C/EBPβ and may serve as an effective anti-obesity compound.

Introduction

Obesity is a major risk factor for hyperglycemia, high blood pressure, and arteriosclerosis, leading to various chronic diseases such as diabetes, cardiovascular disease, and cancer. Therefore, it is very important to prevent obesity. Currently, the anti-obesity effects of food ingredients are drawing attention. Obesity is a condition in which adipose tissue accumulates triacylglycerol (TG) because of an increase in the number of adipocytes and enlargement of adipocytes. Adipose tissue is an endocrine organ that secretes various adipocytokines and serves as an energy storage organ [1]. It changes the balance of adipocytokine secretion depending on the size of adipocytes and contributes to the development of lifestyle-related diseases and atherosclerosis. Therefore, a reduction in the number of adipocytes and suppression of adipocyte hypertrophy are important anti-obesity effects.

Carob (Ceratonia siliqua L.) is an evergreen tree of the genus Locust and is cultivated mainly in the Mediterranean region. After roasting carob pods, the crushed remnant is called carob pod powder, which is used as a substitute for cocoa powder because of its color and flavor [2]. Carob pods also contain polyphenols and minerals, such as calcium, phosphorus, and potassium. Previously, it was reported that in vivo and in vitro antioxidant activity is associated with the polyphenol concentration in carob pod extracts [3]. Therefore, the antioxidant activities of their polyphenols are thought to be associated with the various physiological and pharmacological actions of Carob pods. In an in vitro study using a β-carotene bleaching assay, Kumazawa et al. reported that carob pod polyphenols (CPPs) had stronger antioxidant effects against the discoloration of β-carotene than catechins and procyanidins [3]. Furthermore, several in vivo models have demonstrated that carob pods have hepatoprotective effects against carbon tetrachloride-induced toxicity [4] or ethanol-induced liver injury [5], gastroprotective effects against ethanol-induced oxidative stress [6], and antidiabetic effects against alloxan-induced diabetes [7] or streptozotocin-nicotinamide-induced diabetes [8]. However, the anti-obesity effect and its mechanism of action have not been clarified.

In humans and rodents, it has been suggested that an increase in free and saturated fatty acids by consuming a high fat diet enhances adipogenesis and induces an inflammatory response underlying metabolic syndrome [9, 10]. Therefore, examining the anti-obesity effect of carob pod extract under the intake of a high fat diet in mice is very important to determine the effect of carob pod extract in preventing metabolic syndrome. In the present study, we used a polyphenol-rich fraction eluted with methanol from an HP-20 adsorption resin column as the CPPs.

CPPs have been reported to have preventive effects against liver injury and antidiabetic effects due to their strong antioxidant activity. However, it is not clear whether CPPs can suppress obesity, which causes lifestyle-related diseases. Therefore, the purpose of the present study was to clarify whether CPPs have an anti-obesity effect using an in vivo mouse model and an in vitro cell model. First, the presence or absence of the anti-obesity effect of CPPs was confirmed using an in vivo model with a high fat-induced model. The mechanism by which CPPs inhibit the differentiation of preadipocytes into adipocytes was investigated using 3T3-L1 preadipocytes.

Materials and methods

Preparation of CPPs

CPPs were produced by roasting and crushing carob pods in an oven at 120 to 180°C. The carob powder with a roasting time of 30 min was called “Light”, and the sample with a roasting time of 60 min was called “Extra Dark”. Each powder (500 g) was extracted with 2.5 L of methanol at room temperature overnight. Suction filtration was then performed, and the residue was further extracted with methanol with stirring at room temperature overnight. Similarly, after suction filtration, the extracts were combined, and the solvent was removed using an evaporator. The yields of carob pod-Light and carob pod-Extra Dark were 188 and 107 g, respectively. Next, each extract was dissolved in a small amount of water-containing methanol and applied to an open column (5.5 × 50 cm) packed with conditioned HP-20 adsorption resin. The column was repeatedly passed with water to remove water-soluble components such as sugars and amino acids. After that, methanol flowed over the column to elute the polyphenol component adsorbed on the resin. The methanol eluate was evaporated and dried on a vacuum pump. The yields of carbo pod-Light and carbo pod-Extra Dark were 13.7 and 19.1 g, respectively. Total polyphenol content was determined by the Folin-Ciocalteu method [11], and the total polyphenol concentrations for CPP (Light) and CPP (Extra Dark) were 30.9 ± 1.8% and 28.0 ± 1.5%, respectively.

Animal treatment

The study was approved by the Ethics Committee of Laboratory Animals, and the analysis using laboratory animals complied with the regulations of the Osaka City University Laboratory Animal Committee (permission number: S0056). Thirty-six male C57BL/6J mice (8 weeks old) were obtained from Japan SLC (Shizuoka, Japan) and kept in a temperature-controlled room (25°C) with a 12:12 h light/dark cycle (lights were turned on at 8:00 a.m.) in the laboratory animal center of Osaka City University. Extensive care was taken during the experimental procedures to avoid causing any distress to the animals. After preliminary feeding for 8 days, the mice were randomly grouped so that the average weight of each group was equal, divided into the following six groups (6 mice/group), and fed for 52 days: ① control diet group (control), ② high fat diet group (HF), ③ high fat + 0.06% CPP (Light) diet group (HF + 0.06L), ④ high fat + 0.3% CPP (Light) diet group (HF + 0.3L), ⑤ high fat + 0.06% CPP (Extra Dark) diet group (HF + 0.06E), and ⑥ high fat + 0.3% CPP (Extra Dark) diet group (HF + 0.3E). Diet composition was prepared according to the AIN-93M (Table 1). L(-)-Cystine, sucrose, choline hydrogen tartrate, and tert-butylhydroquinone were purchased from FUJIFILM Wako Pure Chemical Corporation, Japan. Casein, corn starch, αcorn starch, soybean oil, cellulose powder, AIN-93M mineral mix, and AIN-93 vitamin mix were purchased from Oriental Yeast Co., Ltd., Japan. Lard was added to the high fat diet. The estimated ratio of fat calories in the diet was 9.8% for the control diet and 59.4% for the high fat diet. Tap water was used as the drinking water. The mice were housed with three mice in one polycarbonate cage bearing stainless steel wire covers (CLEA Japan, Inc., Tokyo, Japan) with clean paper (Japan SLC, Shizuoka, Japan) and a polycarbonate igloo (Animec Ltd., Tokyo, Japan). The animals were handled by the same researcher. Food and water were freely available. Body weight and food intake were measured once every 2–3 days. Food consumption was measured for each cage, so no statistical analysis was performed. On the 52nd day of feeding, after a 5 h fast (free access to water only), the abdomen was opened under isoflurane inhalation anesthesia, and blood was collected from the abdominal vena cava. Thereafter, the liver, epididymal fat, retroabdominal fat, kidney, and spleen were removed. These organs were washed with physiological saline and weighed. The collected blood was centrifuged (3,500 rpm, 4°C, 10 min) using a TOMY MX-160 centrifuge (TOMY SEIKO, Co., LTD., Japan) to obtain the serum. The obtained serum was stored at -80°C until measurement.

Table 1. Diet composition.

Control HF HF HF HF HF
+ 0.06L + 0.3L + 0.06E + 0.3E
Casein 140.000 140.000 140.000 140.000 140.000 140.000
Lard 0 310.000 310.000 310.000 310.000 310.000
L-Cystine 1.800 1.800 1.800 1.800 1.800 1.800
Cornstarch 465.692 233.019 232.419 230.019 232.419 230.019
α-cornstarch 155.000 77.673 77.673 77.673 77.673 77.673
Sucrose 100.000 100.000 100.000 100.000 100.000 100.000
Soybean Oil 40.000 40.000 40.000 40.000 40.000 40.000
Cellulose powder 50.000 50.000 50.000 50.000 50.000 50.000
AIN-93M mineral a) 35.000 35.000 35.000 35.000 35.000 35.000
AIN-93 vitamin b) 10.000 10.000 10.000 10.000 10.000 10.000
Choline Hydrogen Tartrate 2.500 2.500 2.500 2.500 2.500 2.500
tert-Butylhydroquinone 0.008 0.008 0.008 0.008 0.008 0.008
Carob extract (Light) 0 0 0.600 3.000 0 0
Carob extract (Extra Dark) 0 0 0 0 0.600 3.000
Total (g) 1000 1000 1000 1000 1000 1000

a) Composition in g/kg diet: Calcium carbonate, anhydrous, 357.00; potassium phosphate, monobasic, 250.00; sodium chloride, 74.00; potassium sulfate, 46.60; potassium citrate, 28.00; magnesium oxide, 24.00; ferric citrate, 6.06; zinc carbonate, 1.65; manganese carbonate, 0.63; cupric carbonate, 0.324; potassium iodate, 0.01; sodium selenate, anhydrous, 0.01025; ammonium paramolybdate, 4 hydrate, 0.00795; sodium meta-silicate, 9 hydrate, 1.45; chromium potassium sulfate, 12 hydrate, 0.275; lithium chloride, 0.0174; boric acid, 0.0815; sodium fluoride, 0.0635; nickel carbonate, 4 hydrate, 0.0306; ammonium vanadate, 0.0066; powdered sucrose, 209.7832.

b) Composition in g/kg diet: nicotinic acid, 3.000; calcium pantothenate, 1.600; pyridoxine-HCl, 0.700; thiamin-HCl, 0.600; riboflavin, 0.600; folic acid, 0.200; d-biotin, 0.200; vitamin B12 (cyanocobalamin) (0.l % in mannitol), 2.500; vitamin E (all-rac-α-tocopheryl acetate) (500 IU/g), 15.00; vitamin A (all-trans-retinyl palmitate) (500,000 IU/g), 0.800; vitamin D3 (cholecalciferol) (400,000 IU/g), 0.250; vitamin K (phylloquinone), 0.075; Powdered sucrose, 974.655.

Blood biochemical analysis

Blood glucose was measured immediately after blood collection using the Glucose Pilot Blood Glucose Monitoring System. Serum triglyceride (TG) values were measured using a lab assay™ triglyceride (FUJIFILM Wako Pure Chemical Corporation) with the GPO/DAOS method. The serum total cholesterol level was measured using lab assayTM cholesterol (FUJIFILM Wako Pure Chemical Corporation) by the cholesterol oxidase/DAOS method.

Histopathological analysis of liver and retroabdominal adipose tissue

The liver and retroabdominal adipose tissue were fixed with 10% neutral buffered formalin solution, and then paraffin specimens were prepared for hematoxylin and eosin (H&E) staining. Histopathological specimens were photographed using an inverted research microscope IX70 (Olympus Corporation, Japan) and the AdvanView imaging software. Adipocyte size was quantified using ImageJ software. The pathologist was blinded to the groups of mice.

Cell culture

3T3-L1 preadipocytes (JCRB9014) were purchased from the Japanese Cancer Research Resources Bank and maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS). At 2 days after reaching confluence (day 0), adipocyte differentiation was induced with 0.25 μM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 0.2 μM insulin (DMI) in DMEM supplemented with 10% FBS for 2 days. Then, the cells were treated with 0.2 μM insulin in DMEM supplemented with 10% FBS for another 2 days and cultured for an additional 4 days in DMEM with 10% FBS. CPP (Light) and CPP (Extra Dark) were dissolved in dimethyl sulfoxide (DMSO). The final DMSO concentration in the medium was < 0.5%. In all the experiments, control cultures were made up of medium, DMSO, and cells only.

Cell viability measurement (neutral red method)

After culture with test agents, neutral red solution (0.25 mg/ml) was added to the culture at a final concentration of 50 μg/ml neutral red [12]. After incubation at 37°C for 2 h, the cells were rinsed twice with a solution of 1% (v/v) formaldehyde, 1% calcium chloride, and 98% distilled water. Then, the cells were destained with a buffer solution containing 1% (v/v) acetic acid, 50% (v/v) ethanol, and 49% (v/v) distilled water and incubated for 30 min. Lysosomal uptake of neutral red was quantified spectrophotometrically at 540 nm, and viability was calculated as follows:

Viability(%)=A540treatedcells/A540ofappropriatecontrol×100aftercorrectionforbackgroundabsorbance.

Measurement of TG accumulation

We evaluated the degree of differentiation into mature adipocytes, and staining was performed using Oil Red O [13]. The medium of 3T3-L1 adipocytes was removed with an aspirator and washed with 2 ml of Ca++ and Mg++ free-phosphate buffer saline (PBS (-)). Then, after fixing with 60% ethanol, 1 ml of Oil Red O staining solution was added and left at room temperature for 2 h. After washing with 50% ethanol, it was washed twice with 1 ml of ultrapure water and extracted with 1 ml of 2-propanol. The absorbance of the extract was measured at a wavelength of 520 nm using a spectrophotometer (JASCO V-730 BIO Spectrophotometer).

Analysis of glycerol-3-phosphate dehydrogenase (GPDH) activity

3T3-L1 adipocytes were washed twice with 1 ml of PBS (-), and the cells were collected in 350 μl of triethanolamine/EDTA buffer with a cell scraper. Thereafter, the cells were sonicated using a sonicator (BIO RUPTOR, COSMO BIO Co., LTD., Japan). After centrifugation (13,000 rpm, 5 min, 4°C), the supernatant was used for the enzyme assay. The activity of GPDH was calculated using the extinction coefficient of nicotinamide adenine dinucleotide (NADH) of 6.22 mM-1cm-1 and was calculated based on the change in NADH per 3 min [14]. Enzyme activity was expressed as a value relative to the control (100%).

Real-time PCR

Total RNA from 3T3-L1 adipocytes was extracted using a High Pure RNA Isolation Kit (Roche, Germany). Total RNA quality and quantity were evaluated using a 2100 Bioanalyzer (Agilent Technology, USA). cDNA was synthesized using the PrimeScript RT Reagent Kit (TaKaRa Bio Inc., Japan). Real-time PCR was performed using TB Green Premix Ex Taq II (TaKaRa Bio Inc.) according to the manufacturer’s recommendations in a StepOnePlus PCR System (Thermo Fisher Scientific, USA). The primer sequences are shown in Table 2. The mRNA expression levels were normalized to β-actin. The StepOne software v2.2.2 (Thermo Fisher Scientific) was used for delta-delta CT analysis.

Table 2. The sequence of the primers.

Sense Antisense
C/EBPβ 5’-TTCTGTCTGTACGATTGTCAGTGGA-3’ 5’-GGCATGACTGGGCAGGATTA-3’
PPARγ 5’-GGAGCCTAAGTTTGAGTTTGCTGTG-3’ 5’- TGCAGCAGGTTGTCTTGGATG-3’
C/EBPα 5’- TTGAAGCACAATCGATCCATCC-3’ 5’-GCACACTGCCATTGCACAAG-3’
β-actin 5’- CATCCGTAAAGACCTCTATGCCAAC-3’ 5- ATGGAGCCACCGATCCACA-3’

Western blotting

3T3-L1 adipocytes were washed twice with 1 ml of PBS (-), and the cells were collected in 150 μl of RIPA buffer with a cell scraper. Thereafter, the cells were sonicated using a sonicator (BIO RUPTOR, COSMO BIO Co., LTD., Japan). After centrifugation (15,000 rpm, 10 min, 4°C), sample buffer was added to the supernatant and then heated at 90°C for 5 min. The samples were stored at -80°C before use. The protein concentration was assayed using the PierceTM BCA protein assay kit (Thermo Fisher Scientific, USA). Total protein (20 μg) was separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Merck Millipore, USA). Anti-C/EBPβ(H-7) (Santa Cruz Biotechnology), anti-C/EBPα(14AA) (Santa Cruz Biotechnology), or anti-PPAR(E-8) (Santa Cruz Biotechnology) primary antibodies were diluted 1:2000. Furthermore, GAPDH (D16H11)XP rabbit mAb (Cell Signaling Technology, USA) or anti-actin antibody immunoglobulins/biotinylated (Dako, Denmark) as the loading control was diluted to 1:5000. After blocking with 3% bovine serum albumin for 1 h at room temperature, the membrane was incubated with primary antibody overnight at 4°C and then incubated with a secondary antibody. For the secondary antibody, polyclonal goat anti-mouse immunoglobulins/biotinylated (Dako, Denmark) or polyclonal goat anti-rabbit immunoglobulins/biotinylated (Dako, Denmark) was diluted 1:3000. The membrane was visualized using EZ West Lumi One (ATTO Corporation, Japan) in AE-9300 EZ-Capture MG (ATTO). The fluorescence intensity was analyzed using the CS Analyzer ver. 3.0 (ATTO).

Statistical analysis

Data are presented as mean ± SEM. Statistical analysis was performed using Statcel3, a useful add-in form, in Excel statistical software (OMS publishing Inc., Japan). For multiple comparisons, Dunnett’s method was used in in vivo experiments, and the Tukey-Kramer method was used in in vitro experiments. A significant difference test was performed at a risk rate of 5% or 1%.

Results

Effect of CPPs on body weight

To determine the effect of a diet containing CPPs in C57BL/6J mice fed a high fat diet, we measured the body weights of the mice. The weight increased significantly in the HF group compared with the control group. However, there was a tendency for body weight to decrease in the CPP intake group with the HF group. In particular, in the HF + 0.06 L group, there was a significant decrease compared with the HF group (Fig 1).

Fig 1. Effect of CPP on body weight.

Fig 1

Control; Control food group, HF; High fat diet group, HF + 0.06L; High fat + 0.06% CPP (Light) diet group, HF + 0.3L; High fat + 0.3% CPP (Light) diet group, HF + 0.06E; High fat + 0.06% CPP (Extra Dark) diet group, HF + 0.3E; High fat + 0.3% CPP (Extra Dark) diet group. Values are means ± SEM of six mice. **; p < 0.01, *; p < 0.05 vs HF.

Effect of CPPs on visceral fat weight of mice

To examine whether the body weight gain in CPP-treated groups resulted in decreased fat accumulation, the visceral fat weight was examined. Visceral fat weight was significantly increased by a high fat diet. However, ingesting CPPs tended to decrease epididymal fat weight, and retroabdominal fat weight significantly decreased (Fig 2).

Fig 2.

Fig 2

Effects of CPP on epididymal fat weight (A) and retroabdominal fat weight (B). Control; Control food group, HF; High fat diet group, HF + 0.06L; High fat + 0.06% CPP (Light) diet group, HF + 0.3L; High fat + 0.3% CPP (Light) diet group, HF + 0.06E; High fat + 0.06% CPP (Extra Dark) diet group, HF + 0.3E; High fat + 0.3% CPP (Extra Dark) diet group. Values are means ± SEM of six mice. **; p < 0.01, *; p < 0.05 vs HF.

Effect of CPPs on lipid metabolism of mice

To examine the effect of CPPs on lipid metabolism, we measured the serum total cholesterol levels of the mice. The serum total cholesterol level, which was significantly increased by the high fat diet, tended to decrease by feeding the mice with CPP (Light) (Fig 3). We also performed H&E staining of the liver and observed that in the HF group, lipid droplets accumulated in hepatocytes, and mice exhibited fatty liver. In all CPP-fed groups, fatty liver was remarkably suppressed (Fig 4A). These results were consistent with the liver TG levels (Fig 4B). These results suggest that CPPs inhibit fat accumulation in the liver induced by a high fat diet.

Fig 3. Effect of CPP on the serum total cholesterol levels of mice.

Fig 3

The serum total cholesterol levels were measured by the cholesterol oxidase/DAOS method. Control; Control food group, HF; High fat diet group, HF + 0.06L; High fat + 0.06% CPP (Light) diet group, HF + 0.3L; High fat + 0.3% CPP (Light) diet group, HF + 0.06E; High fat + 0.06% CPP (Extra Dark) diet group, HF + 0.3E; High fat + 0.3% CPP (Extra Dark) diet group. Values are means ± SEM of six mice. **; p < 0.01 vs HF.

Fig 4. Effects of CPP on morphological changes and TG levels in mouse livers.

Fig 4

(A) Liver specimens were stained with H&E staining. (a) Control food group, (b) High fat diet group, (c) High fat + 0.06% CPP (Light) diet group, (d) High fat + 0.3% CPP (Light) diet group, (e) High fat + 0.06% CPP (Extra Dark) diet group, (f) High fat + 0.3% CPP (Extra Dark) diet group. Original magnification: 20×. (B) Liver TG levels of mice were measured by the GPO/DAOS method. Control; Control food group, HF; High fat diet group, HF + 0.06L; High fat + 0.06% CPP (Light) diet group, HF + 0.3L; High fat + 0.3% CPP (Light) diet group, HF + 0.06E; High fat + 0.06% CPP (Extra Dark) diet group, HF + 0.3E; High fat + 0.3% CPP (Extra Dark) diet group. Values are means ± SEM of six mice. **; p < 0.01, *; p < 0.05 vs HF.

Effect of CPPs on morphological changes in adipose tissue of mice

In the HF group, adipocyte hypertrophy was observed (Fig 5A). In addition, as shown by the arrow, many characteristic histological images associated with obesity were observed, in which macrophages surrounded the adipocytes that had died (crown-like structure, CLS). In the CPP-fed groups, macrophage infiltration was reduced. The intake of a high fat diet significantly increased the size of adipocytes. However, when CPPs were fed a high fat diet, adipocyte hypertrophy was significantly suppressed (Fig 5B).

Fig 5.

Fig 5

Effects of CPP on (A) morphological changes and (B) the size of adipocytes in adipose tissue of mice. (A) Retroabdominal adipose tissue specimens were stained with H&E. (a) Control food group, (b) High fat diet group, (c) High fat + 0.06% CPP (Light) diet group, (d) High fat + 0.3% CPP (Light) diet group, (e) High fat + 0.06% CPP (Extra Dark) diet group, (f) High fat + 0.3% CPP (Extra Dark) diet group. Original magnification: 10×. Arrow indicated a crown-like structure. (B) The size of adipocytes in retroabdominal adipose tissue specimens stained with H&E was quantified using ImageJ. Control; Control food group, HF; High fat diet group, HF + 0.06L; High fat + 0.06% CPP (Light) diet group, HF + 0.3L; High fat + 0.3% CPP (Light) diet group, HF + 0.06E; High fat + 0.06% CPP (Extra Dark) diet group, HF + 0.3E; High fat + 0.3% CPP (Extra Dark) diet group. Values are means ± SEM of six mice. **; p < 0.01, *; p < 0.05 vs HF.

Effect of CPPs (Light and Extra Dark) treatment on the viability of 3T3-L1 preadipocytes

Cell viability of 3T3-L1 preadipocytes was examined with CPPs (Light and Extra Dark) by Neutral red assay. As shown in Fig 6A and 6B, neither type of CPP (Light or Extra Dark) had any effect on cell viability at concentrations of up to 100 μg/ml. These results showed that CPPs are not cytotoxic to 3T3-L1 preadipocytes.

Fig 6. Effect of CPPs (Light and Extra Dark) on cell viability of 3T3-Li preadipocytes.

Fig 6

Cells were cultured for 24 h with 50, 100, or 200 μg/ml CPPs (Light (A) and Extra Dark (B)). Cell viability was measured with Neutral red assay. Values are means ± SEM (n = 4). *; p < 0.05 vs Control.

Effect of CPP treatment on TG accumulation in 3T3-L1 preadipocytes

Intracellular TG was stained using the Oil Red O staining method. TG accumulation was significantly reduced in CPP (Light)-treated cells compared with CPP (Extra Dark)-treated cells. Furthermore, when CPP (Light) was added to 3T3-L1 preadipocytes at a concentration of 50 or 100 μg/ml, TG accumulation was significantly reduced, depending on the concentration of CPP (Light) (Fig 7A and 7B). Therefore, the following experiments were performed using CPP (Light).

Fig 7. Effect of CPP on TG accumulation of 3T3-L1 preadipocytes.

Fig 7

Intracellular TG was stained using the Oil Red O staining method. Oil Red O staining was performed 8 days after the initiation of differentiation. Representative photos of Oil Red O staining and quantitative analyses of 3T3-L1 preadipocytes treated with or without (A) 100 μg/ml CPP (Light or Extra Dark) or (B) 50 or 100 μg/ml CPP (Light). Oil Red O was extracted, and the absorbance of the extract was measured at a wavelength of 520 nm using a spectrophotometer. Values are means ± SEM (n = 4). **; p < 0.01 vs Control.

Effect of CPP (Light) on GPDH activity in 3T3-L1 preadipocytes

To ascertain the reduction of TG accumulation in 3T3-L1 preadipocytes treated with CPPs, we examined the effect of CPP (Light) on GPDH activity, a rate-limiting enzyme in TG synthesis. As shown in Fig 8, GPDH activity was significantly reduced, depending on the concentration of CPP (Light).

Fig 8. Effect of CPP (Light) on GPDH activity in 3T3-L1 preadipocytes.

Fig 8

The activity of GPDH was calculated using the extinction coefficient of NADH, 6.22 mM-1 cm-1, and was calculated based on the decrease in NADH every 3 min. Enzyme activity is expressed as a value relative to the control (100%). Values are means ± SEM (n = 4). **; p < 0.01 vs Control.

Effect of the addition period of CPP (Light) on fat accumulation in 3T3-L1 preadipocytes

To clarify at which stage of differentiation that CPP (Light) is acting, an experiment was conducted by changing the sample addition period during the induction of differentiation (Fig 9A). When CPP (Light) was added on Day 0, intracellular TG accumulation decreased significantly. However, the addition of CPP (Light) after Day 2 had no effect on the intracellular TG level, showing that CPP (Light) acts at the early stages of adipocyte differentiation (Fig 9B).

Fig 9. Effect of the addition period of CPP (Light) on fat accumulation in 3T3-L1 preadipocytes.

Fig 9

(A) The schema shows the addition of CPP (Light) during the induction of differentiation. Oil Red O staining was performed 8 days after the initiation of differentiation. (B) Oil Red O was extracted, and the absorbance of the extract was measured at a wavelength of 520 nm using a spectrophotometer. Values are means ± SEM (n = 4). **; p < 0.01 vs Control.

Effect of CPP (Light) treatment on mitotic clonal expansion (MCE) after inducing 3T3-L1 preadipocyte differentiation

Adipocytes stop growing as soon as they become confluent, but when stimulated to induce differentiation, the cell cycle progresses again and undergoes several MCEs to differentiate into adipocytes. Because CPP (Light) treatment acted in the early stage of differentiation, we thought that it might suppress MCE because of differentiation induction. Therefore, we examined the cell number by Trypan blue staining. Because of differentiation induction, MCE was significantly suppressed 48 h after the addition of carob extract (Fig 10).

Fig 10. Effect of CPP (Light) on mitotic clonal expansions after inducing 3T3-L1 preadipocyte differentiation.

Fig 10

The cell number was measured with Trypan blue staining at 48 h after inducing 3T3-L1 preadipocyte differentiation. Values are means ± SEM (n = 3). Values without a common letter are significantly different (p < 0.05).

Effect of transcription factors involved in adipocyte differentiation in 3T3-L1 preadipocytes

Expression of the transcription factors involved in adipocyte differentiation was examined by real-time PCR for gene expression and western blotting for protein expression.

In adipocytes, the expression of C/EBPβ and C/EBPδ is induced in the early stage of differentiation, which is followed by the expression of PPARγ and C/EBPα, which are the master regulators of adipocyte differentiation.

The effect of CPP (Light) treatment on the expression of C/EBPβ was investigated. C/EBPβ is an important factor in MCE during early differentiation. At 48 h after the induction of differentiation, the gene expression levels of C/EBPβ did not change, even when CPP (Light) was added. However, the protein levels decreased significantly, depending on the concentration of CPP (Light) (Fig 11A and 11B). Therefore, it was revealed that the expression of C/EBPβ was regulated posttranscriptionally.

Fig 11. Effects of CPP (Light) on (A) the gene expression and (B) protein levels of C/EBPβ.

Fig 11

(A) mRNA expression of C/EBPβ was analyzed with real-time PCR 48 h after induction of 3T3-L1 preadipocyte differentiation. Values are means ± SEM (n = 4). (B) C/EBPβ; protein levels were measured with western blotting 48 h after the induction of 3T3-L1 preadipocyte differentiation. Values are means ± SEM (n = 3). **; p < 0.01, *; p < 0.05 vs Control.

The effect of CPP treatment on the expression of PPARγ was investigated. CPP (Light) treatment significantly reduced PPARγ gene expression levels at both 24 and 48 h after the induction of differentiation (Fig 12A and 12B). By adding 100 μg/ml CPP (Light), PPARγ protein levels tended to decrease at 48 h and significantly decreased 72 h after the induction of differentiation (Fig 12C and 12D). Therefore, it was shown that CPP continuously reduced the PPARγ gene expression level starting at 24 h after the induction of differentiation and reduced the protein level after 72 h.

Fig 12.

Fig 12

Effects of CPP (Light) on (A, B) the gene expression and (C, D) protein levels of PPARγ. (A, B) mRNA expression of PPARγ was analyzed with real-time PCR 24 h (A) or 48 h (B) after induction of 3T3-L1 preadipocyte differentiation. Values are means ± SEM (n = 4). **; p < 0.01 vs Control. (C, D) PPARγ protein levels were measured with western blotting 48 h (C) or 72 h (D) after induction of 3T3-L1 preadipocyte differentiation. Values are means ± SEM (n = 3). **; p < 0.01, *; p < 0.05 vs Control.

The effect of CPP (Light) treatment on the expression of C/EBPα was investigated. At 24 h after the induction of differentiation, the gene expression levels and protein levels of C/EBPα did not change, even when CPP (Light) was added (Fig 13A–13C). C/EBPα gene expression and protein levels at 48 h were significantly reduced by the addition of CPP (Light) (Fig 13B–13D). Therefore, the expression of C/EBPα was suppressed at 24–48 h after the induction of differentiation by adding CPPs.

Fig 13.

Fig 13

Effects of CPP (Light) on (A, B) the gene expression and (C, D) protein levels of C/EBPα. (A, B) mRNA expression of C/EBPα was analyzed with real-time PCR 24 h (A) or 48 h (B) after induction of 3T3-L1 preadipocyte differentiation. Values are means ± SEM (n = 4). **; p < 0.01, *; p < 0.05 vs Control. (C, D) C/EBPα protein levels were measured with western blotting 24 h (C) or 48 h (D) after induction of 3T3-L1 preadipocyte differentiation. Values are means ± SEM (n = 3). **; p < 0.01 vs Control.

Discussion

The present study revealed that the carob extract significantly suppressed the increase in adipose tissue weight and adipocyte hypertrophy in the in vivo experimental system. Moreover, in the in vitro experimental system, CPP (Light) treatment acted at the early stages of differentiation of 3T3-L1 preadipocytes and suppressed cell proliferation because of differentiation induction. It suppressed the expression of transcription factors involved in adipocyte differentiation, reducing TG synthesis ability and TG accumulation. In addition, an interesting finding is that CPPs treatment was found to regulate C/EBPβ expression at the early stage of differentiation at the posttranscriptional level.

In the in vivo experiment, we observed by histological analysis that the liver of the high fat diet group was a fatty liver. In the CPP-fed group, on the other hand, the occurrence of fatty liver was significantly suppressed (Fig 4A). Furthermore, the liver TG levels were also significantly increased by the high fat diet but decreased by feeding the mice CPPs (Fig 4B). These results suggest that CPPs inhibit fat accumulation in the liver induced by a high fat diet.

M1 macrophages, which increase with obesity, show a characteristic histology (crown-like structure, CLS) that surrounds adipocytes and secretes many inflammatory cytokines to promote inflammatory changes in adipose tissue [15]. In the present study, the histopathological analysis of retroperitoneal adipose tissue showed that fat cell hypertrophy and characteristic CLS were associated with obesity in the HF group (Fig 5A). However, when CPPs were fed a high fat diet, the hypertrophy of adipocytes was significantly suppressed (Fig 5B); the carob extract also reduced CLS. Therefore, CPPs were suggested to suppress fat cell hypertrophy and macrophage infiltration into fat cells induced by a high fat diet.

When CPP (Light) was added to 3T3-L1 preadipocytes at a concentration of 50 or 100 μg/ml, TG accumulation was significantly reduced, depending on the concentration of CPP (Light) (Fig 7B). The addition of CPP (Light) to preadipocytes from the induction of differentiation reduced TG accumulation. These results suggest that CPPs have a “preventive” effect in obesity.

To clarify the stage at which differentiation CPP (Light) acts, we examined the sample addition period during the induction of differentiation. Only in the group to which CPP (Light) was added from the start of differentiation induction was intracellular TG accumulation significantly reduced. Therefore, it was revealed that CPP (Light) treatment acts at the early stage of adipocyte differentiation.

Adipocytes stop proliferating as soon as they become confluent, but upon receiving a differentiation-inducing stimulus, progress through the cell cycle starts again and undergoes several MCEs to differentiate into adipocytes [16]. Because CPP (Light) treatment acts at the early stage of differentiation, it might suppress MCE by the induction of differentiation; here, the cell number was examined by Trypan blue staining. MCE induced by differentiation was significantly suppressed 48 h after the addition of carob extract (Fig 10).

The expression of the transcription factors involved in adipocyte differentiation was examined by real-time PCR for gene expression and western blotting for protein expression. In adipocytes, the expression of C/EBPβ and C/EBPδ is induced in the early stage of differentiation, and gene expression reaches a peak 1–2 days after the induction of differentiation [17]. These transcription factors induce the expression of PPARγ and C/EBPα, which are the master regulators of adipocyte differentiation [18, 19]. PPARγ and C/EBPα do not function independently but maintain their expression in cooperation with each other and induce the expression of adipocyte differentiation markers [20].

First, the effect of CPP treatment on C/EBPβ expression was examined. C/EBPβ is an important factor in MCE during early differentiation [21]. Indeed, 48 h after the induction of differentiation, the gene expression level of C/EBPβ did not change when CPP (Light) was added (Fig 11A). On the other hand, the protein levels decreased significantly, depending on the concentration of CPP (Light) (Fig 11B). Therefore, the expression of C/EBPβ appeared to be regulated post-transcriptionally.

Next, the effect of CPP treatment on the expression of PPARγ was examined. CPP (Light) treatment significantly reduced the level of PPARγ gene expression 24 h (Fig 12A) and 48 h (Fig 12B) after induction of differentiation. By adding CPP (Light) at 100 μg/ml, PPARγ protein levels tended to decrease 48 h after induction of differentiation (Fig 12C) and significantly decreased after 72 h (Fig 12D). Therefore, it was shown that CPPs continuously reduced the PPARγ gene expression levels from 24 h after the induction of differentiation and reduced the protein levels after 72 h. Furthermore, the effect of CPP (Light) treatment on the expression of C/EBPα was examined. At 24 h after the induction of differentiation, the gene expression levels of C/EBPα (Fig 13A) and protein levels (Fig 13C) were not changed by the addition of CPP (Light). At 48 h, the levels of C/EBPα gene expression (Fig 13B) and protein levels (Fig 13D) were significantly reduced by the addition of CPP (Light). Therefore, the expression of C/EBPα was suppressed 24 to 48 h after the induction of differentiation by adding CPPs.

The effect of CPP (Light) treatment on the expression of a transcription factor (C/EBPβ, PPARγ, and C/EBPα) involved in adipocyte differentiation is shown in Scheme 1.

Scheme 1. Effect of CPP on the expression of transcription factors in the differentiation of 3T3-L1 preadipocytes.

Scheme 1

→; no effect, ↓; down regulation.

C/EBPβ was posttranscriptionally regulated by CPP (Light) treatment. It has been reported that the stability of C/EBPβ protein is increased by oxidative modification (S-glutathionization). In 3T3-L1 cells, glutaredoxin, an enzyme that catalyzes de-S-glutathionase, was knocked out, S-glutathionisation increased, fat synthesis was promoted, and PPARγ, C/EBPα, and C/EBPβ expression increased. It has been suggested that C/EBPβ expression is regulated at the protein level [22]. CPPs have been reported to have antioxidant activity, indicating that in the current study, CPP (Light) treatment inhibited the oxidative modification of C/EBPβ protein, resulting in C/EBPβ not being able to acquire stability and degradation.

Finally, we also wanted to elucidate the active substance of the carob extract, which has an anti-obesity effect. Carob pods are rich in polyphenols (tannins, flavonoids, and phenolic acids) [23]. Carobs have been reported to reduce hydrolyzable tannins and increase gallic acid through the process of roasting [24]. In preliminary experiments, we found in studies using 3T3-L1 preadipocytes that gallic acid has no anti-obesity effect (unpublished data). Therefore, it is suggested that CPP (Extra Dark) carob pods roasted for a long time had a lower anti-obesity effect than CPP (Light) due to a decrease in unknown components having an anti-obesity effect and an increase in gallic acid, which had no anti-obesity effect. In addition, catechins form tannins through oxidation and polymerization. This suggests that CPP (Extra Dark) was not as effective as CPP (Light) because the polymerization of polyphenols progressed during roasting. It is thought that the combination of components, such as the proanthocyanidin-based polymerized catechins contained in CPPs, exerts an anti-obesity effect, but isolating the active substance for identification is currently difficult. It is necessary to further study the isolation and purification of polymerized polyphenols.

In conclusion, these results demonstrated that CPPs suppressed the differentiation of adipocytes through the posttranscriptional regulation of C/EBPβ and may be an effective anti-obesity compound.

Supporting information

S1 Raw images. Original images of Figs 11B, 12C, 12D, 13C and 13D.

(PDF)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by JSPS KAKENHI (Grant Number JP15K00832). KAKENHI aims to significantly develop all "academic research" from basic to applied (research based on the free thinking of researchers). TAISHO TECHNOS, Co., Ltd. provided the Carob pod polyphenols, a part of the grant, and support in the form of salary for T.S., but did not have any additional role in the study design data collection and analysis decision to publish, or preparation of the manuscript. The specific role of T.S. is articulated in the “Author Contributions” section.

References

  • 1.Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 14(6), 561–566. 10.1097/00041433-200312000-00003 [DOI] [PubMed] [Google Scholar]
  • 2.Yousif AK, Alghzawi HM. (2000) Processing and characterization of carob powder. Food Chem. 69(3), 283–287. [Google Scholar]
  • 3.Kumazawa S, Taniguchi M, Suzuki Y, Shimura M, Kwon MS. et al. (2002) Antioxidant activity of polyphenols in carob pods. J. Agric. Food Chem. 50(2), 373–277. 10.1021/jf010938r [DOI] [PubMed] [Google Scholar]
  • 4.Suzek H, Celik I, Dogan A. (2017) Nephropritective hepatoprotective potential and antioxidant role of carob pods (Celotonia silique L.) against carbon tetrachloride-induced toxicity in rats. Ind. J. pharmacol. Educat. Res. 51, 312–320. [Google Scholar]
  • 5.Souli A, Sebai H, Chehimi L, Rtibi K, Tounsi H, et al. (2013) Hepatoprotective effect of carob against acute ethanol-induced oxidative stress in rat. Toxicol. Industr. Health, 10.1177/0748233713475506 [DOI] [PubMed] [Google Scholar]
  • 6.Rtibi K, Jabri MA, Selmi S, Soul A, Sebai H, et al. (2015) Gastroprotective effect of carob (Ceratonia Siliqua L.) against ethanol-induced oxidative stress in rat. BMC Complem Aitern M 10.1186/s12906-015-0819-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rtibi K, Selmi S, Grami D, Saidani K, Sebai H, et al. (2016) Ceratonia silique l. (immature carbo bean) inhibits intestinal glucose absorption, improves glucose tolerance and protects against alloxan-induced diabetes in rat. J. Sci. Food Agric. 97(8), 2664–2670. 10.1002/jsfa.8091 [DOI] [PubMed] [Google Scholar]
  • 8.Qasem MA, Noordin MI, Arya A, Alsalahi A, Jayash SN. (2018) Evaluation of the glycemic effecof Ceratonia silique pods (Carob) on a streptozotosin-nicitinianide induced diabetic rat model. 10.7717/peerj.4788 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Woods SC, Seeley RJ, Rushing PA, D’Alessio D, Tso P. (2003) A controlled high-fat diet induces an obese syndrome in rats. J. Nutr. 133(4), 1081–1087. 10.1093/jn/133.4.1081 [DOI] [PubMed] [Google Scholar]
  • 10.Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A. (2003) Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52(12), 2882–2887. 10.2337/diabetes.52.12.2882 [DOI] [PubMed] [Google Scholar]
  • 11.Ragazzi E (1973) Quantitative analysis of phenolic compounds after thin-layer chromatographic separation. J. Chromatogr. 77(2), 369–375. 10.1016/s0021-9673(00)92204-0 [DOI] [PubMed] [Google Scholar]
  • 12.Riddell RJ, Clothier RH, Balls M. (1986) An evaluation of three in vitro cytotoxicity assays. Food Chem. Toxicol. 24(6–7), 469–471. 10.1016/0278-6915(86)90095-5 [DOI] [PubMed] [Google Scholar]
  • 13.Ramírez-Zacarías JL, Castro-Muñozledo F, Kuri-Harcuch W. (1992) Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 97, 493–497. 10.1007/BF00316069 [DOI] [PubMed] [Google Scholar]
  • 14.Weis LS, Green H. (1979) Participation of one isozyme of cytosolic glycerophosphate dehydrogenase in the adipose conversion of 3T3 cells. J. Biol. Chem. 254(2), 273–275. [PubMed] [Google Scholar]
  • 15.Tanaka M, Ikeda K, Suganami T, Komiya C, Ochi K, et al. (2014) Macrophage-inducible C-type lectine underlies obesity-induced adipose tissue fibrosis. Nature Commun. 5, 4982 10.1038/ncomms5982 [DOI] [PubMed] [Google Scholar]
  • 16.Georgoire FM, Smas CM, Sul HS. (1998) Understanding adipocyte differentiation. Physiol. Rev. 78(3), 783–809. 10.1152/physrev.1998.78.3.783 [DOI] [PubMed] [Google Scholar]
  • 17.Vasseur-Cognet M, Lane MD. (1993) Trans-acting factors involved in adipogenic differentiation. Curr Opin. Genet. Dev. 3(2), 238–245. 10.1016/0959-437x(93)90029-o [DOI] [PubMed] [Google Scholar]
  • 18.Cao Z, Umek RM, McKnight SL. (1991) Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 5(9), 1538–1552. 10.1101/gad.5.9.1538 [DOI] [PubMed] [Google Scholar]
  • 19.Wu Z, Bucher NL, Farmer SR. (1996) Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids. Mol. Cell Biol. 16(8), 4128–4136. 10.1128/mcb.16.8.4128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.MacDougald OA, Lane MD. (1995) Transcriptional regulation of gene expression during adipocyte differentiation. Annu. Rev. Biochem. 64, 345–373. 10.1146/annurev.bi.64.070195.002021 [DOI] [PubMed] [Google Scholar]
  • 21.Tang Q-Q, Otto TC & Lane MD. (2003) CCAAT/enhancer-binding protein b is required for mitotic clonal expansion during adipogenesis. Proc. Natl. Acad. Sci. USA 100(3), 850–855. 10.1073/pnas.0337434100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Watanabe Y, Watanabe K, Fujioka D, Nakamura K, Nakamura T, et al. (2020) Protein S-glutathionylation stimulate adipogenesis by stabilizing C/EBPβ in 3T3L1 cells. FASEB J. 34(4). 827–837. 10.1096/fj.201902575R [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Stavrou IJ, Christou A & Kapnissi-Christodoulou CP. (2018) Polyphenols in carobs: A review on their composition, antioxidant capacity and cytotoxic effects, and health impact. Food Chem. 269, 355–374. 10.1016/j.foodchem.2018.06.152 [DOI] [PubMed] [Google Scholar]
  • 24.Papagiannopoulos M, Wollseifen HR, Mellenthin A, Haber B, Galensa R, (2004) Identification and quantification of polyphenols in Carob fruits (Ceratonia siliqua L.) and derived products by HPLC-UV-ESI/MSn. J. Agric. Food Chem. 52(12), 3784–3791. 10.1021/jf030660y [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Juan J Loor

25 Jan 2021

PONE-D-20-38421

Carob pod polyphenols suppress the differentiation of adipocytes through posttranscriptional regulation of C/EBPß

PLOS ONE

Dear Dr. Kojima-Yuasa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 01 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Juan J Loor

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Competing Interests section:

"The authors have declared that no competing interests exist."

We note that one or more of the authors are employed by a commercial company: TAISHO TECHNOS, Co., Ltd.

2.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5. Please include a caption for figures 13A-D.

6. Please ensure that you refer to Figures 13A-D in your text as, if accepted, production will need this reference to link the reader to the figure.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: There is a major problem in lining up your figures/data with the descriptions in the text. For example on line 294, it states that Fig 7 displays the effect of CPP (Light) on GPDH activity. However, in the text figures these enzyme activity results are in Fig 8. The problem appears to be that the data for CPP treatment on TG accumulation was to be Fig 6, but in the MS Fig 6 is about adiponectin and the data are missing. From that point on all figures are off, ie Fig 6 is really Fig 7 etc. These presentation errors must be corrected. Somehow the adiponectin results seem to have been deleted from the MS, but the Figure #s were never adjusted.

Overall the presentation appears somewhat "unconcise", this reviewer did not like a short results description in the text and this was followed by the legend of the Fig for those results in the complete MS.

Fortunately the discussion does enlighten the readers and I believe the research work was done properly. But again the layout of the MS requires work .

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 8;16(3):e0248073. doi: 10.1371/journal.pone.0248073.r002

Author response to Decision Letter 0


13 Feb 2021

RESPONSES TO COMMENTS BY THE ACADEMIC EDITOR AND REVIEWER #1

(PONE-D-20-38421)

We would like to thank your valuable comments for the helpful constructive comments and suggestions on our manuscript entitled “Carob pod polyphenols suppress the differentiation of adipocytes through posttranscriptional regulation of C/EBP�”.

Below are our responses to the concerns raised by the Academic editor and Reviewer #1. There reviews were thorough and we are grateful for their contributions and have addressed each one of these.

We sincerely believe our manuscript is now much improved.

Responses to “Journal Requirements”:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

→ We checked our manuscript according to PLOS ONE’s style.

2.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

→ Thank you very much for your kindly comments and valuable suggestions. We added the Funding and Competing interest as following in red characters (Page 28, Line 517 to 528).

Funding

This work was supported by JSPS KAKENHI (Grant Number JP15K00832). KAKENHI aims to significantly develop all "academic research" from basic to applied (research based on the free thinking of researchers). TAISHO TECHNOS, Co., Ltd. provided the Carob pod polyphenols, a part of the grant, and support in the form of salary for T.S., but did not have any additional role in the study design data collection and analysis decision to publish, or preparation of the manuscript. The specific role of T.S. is articulated in the “Author Contributions” section.

Competing interests

A part of research grant and Carob pod polyphenols were provided by the TAISHO TECHNOS, Co., Ltd. We declare that these relationships did not affect the results and conclusions of this manuscript. This does not alter on adherence to PLOS ONE politics on sharing data and materials.

2.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.”

If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter.

→ Thank you very much for your valuable suggestions. We added the Competing interest as following in red characters (Page 28, Line 525 to 528).

Competing interests

A part of research grant and Carob pod polyphenols were provided by the TAISHO TECHNOS, Co., Ltd. We declare that these relationships did not affect the results and conclusions of this manuscript. This does not alter on adherence to PLOS ONE politics on sharing data and materials.

And we included both an updated Funding Statement and Competing Interests Statement in our cover letter.

3. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository.

→ Thank you very much for your valuable suggestions. We added the three supplemental files of the original underlying images for all blot. And we wrote about it in our cover letter.

4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

→ Thank you very much for your kindly comments and valuable suggestions. We have included 3 phrases “data not shown” in our manuscript.

1) The data of organ weight are not a core part of our research, so we changed as following,

Effect of CPPs on organ weight of mice

There was no significant difference in the liver, kidney, or spleen weights in each group (data not shown). Visceral fat weight was significantly increased by a high-fat diet. However, ingesting CPPs tended to decrease epididymal fat weight, and retroabdominal fat weight significantly decreased (Fig. 2).

              ↓

Effect of CPPs on visceral fat weight of mice

To examine whether the body weight gain in CPP-treated groups resulted in decreased fat accumulation, the visceral fat weight was examined. Visceral fat weight was significantly increased by a high-fat diet. However, ingesting CPPs tended to decrease epididymal fat weight, and retroabdominal fat weight significantly decreased (Fig. 2).

(Page14, Line 255 to 256)

2) The data of serum glucose concentrations are not a core part of our research, so we changed as following,

Effect of CPPs on serum glucose and total cholesterol levels of mice

There were no significant differences in serum glucose concentrations between groups (data not shown). In this experiment, the serum total cholesterol level of the mice, which was significantly increased by the high-fat diet, tended to decrease by feeding the mice CPP (Light) (Fig. 3).

Effect of CPPs on lipid metabolism of mice

To examine the effect of CPPs on lipid metabolism, we measured the serum total cholesterol levels of the mice. The serum total cholesterol level, which was significantly increased by the high fat diet, tended to decrease by feeding the mice with CPP (Light) (Fig. 3). We also performed H&E staining of the liver and observed that in the HF group, lipid droplets accumulated in hepatocytes, and mice exhibited fatty liver. In all CPP-fed groups, fatty liver was remarkably suppressed (Fig. 4A). These results were consistent with the liver TG levels (Fig. 4B). These results suggest that CPPs inhibit fat accumulation in the liver induced by a high fat diet.

(Page15, Line 266 to 273)

3) We added the new figure as Fig.6.

Effect of CPPs (Light and Extra Dark) treatment on the viability of 3T3-L1 preadipocytes

Neither type of CPPs (Light or Extra Dark) had any effect on cell viability at concentrations of up to 100 μg/ml (data not shown).

Effect of CPPs (Light and Extra Dark) treatment on the viability of 3T3-L1 preadipocytes

Cell viability of 3T3-L1 preadipocytes was examined with CPPs (Light and Extra Dark) by Neutral red assay. As shown in Fig. 6A and B, neither type of CPP (Light or Extra Dark) had any effect on cell viability at concentrations of up to 100 g/ml. These results showed that CPPs are not cytotoxic to 3T3-L1 preadipocytes.

(Page17, Line 311 to 316)

5. Please include a caption for figures 13A-D. 

6. Please ensure that you refer to Figures 13A-D in your text as, if accepted, production will need this reference to link the reader to the figure.

→ We are grateful for pointing out our carelessness. We removed incorrect figure legends, and changed correct figure legends of Fig. 7-12.

Responses to “Comments”:

We would like to thank your constructive suggestions.

There is a major problem in lining up your figures/data with the descriptions in the text. For example on line 294, it states that Fig 7 displays the effect of CPP (Light) on GPDH activity. However, in the text figures these enzyme activity results are in Fig 8. The problem appears to be that the data for CPP treatment on TG accumulation was to be Fig 6, but in the MS Fig 6 is about adiponectin and the data are missing. From that point on all figures are off, ie Fig 6 is really Fig 7 etc. These presentation errors must be corrected. Somehow the adiponectin results seem to have been deleted from the MS, but the Figure #s were never adjusted.

→ We are grateful for pointing out our carelessness. We removed incorrect figure legends, and changed correct figure legends of Fig. 7-12. We removed the figure legend of adiponectin results.

Overall the presentation appears somewhat "unconcise", this reviewer did not like a short results description in the text and this was followed by the legend of the Fig for those results in the complete MS.

→ Thank you very much for your valuable suggestions.

We added the sentences as following,

Effect of CPPs on body weight

To determine the effect of a diet containing CPPs in C57BL/6J mice fed a high fat diet, we measured the body weights of the mice. The weight increased significantly in the HF group compared with the control group. However, there was a tendency for body weight to decrease in the CPP intake group with the HF group. In particular, in the HF + 0.06 L group, there was a significant decrease compared with the HF group (Fig. 1).

(Page13, Line 241 to 246)

Effect of CPPs on visceral fat weight of mice

To examine whether the body weight gain in CPP-treated groups resulted in decreased fat accumulation, the visceral fat weight was examined. Visceral fat weight was significantly increased by a high fat diet. However, ingesting CPPs tended to decrease apididymal fat weight, and retroabdominal fat weight significantly decreased (Fig. 2).

(Page 14, Line 254 to 258)

Effect of CPPs on lipid metabolism of mice

To examine the effect of CPPs on lipid metabolism, we measured the serum total cholesterol levels of the mice. The serum total cholesterol level, which was significantly increased by the high fat diet, tended to decrease by feeding the mice with CPP (Light) (Fig. 3). We also performed H&E staining of the liver and observed that in the HF group, lipid droplets accumulated in hepatocytes, and mice exhibited fatty liver. In all CPP-fed groups, fatty liver was remarkably suppressed (Fig. 4A). These results were consistent with the liver TG levels (Fig. 4B). These results suggest that CPPs inhibit fat accumulation in the liver induced by a high fat diet.

(Page 15, Line 266 to 273)

Effect of CPPs (Light and Extra Dark) treatment on the viability of 3T3-L1 preadipocytes

Cell viability of 3T3-L1 preadipocytes was examined with CPPs (Light and Extra Dark) by Neutral red assay. As shown in Fig. 6A and B, neither type of CPP (Light or Extra Dark) had any effect on cell viability at concentrations of up to 100 g/ml. These results showed that CPPs are not cytotoxic to 3T3-L1 preadipocytes. (Page 17, Line 311 to 321)

Effect of CPP (Light) on GPDH activity in 3T3-L1 preadipocytes

To ascertain the reduction of TG accumulation in 3T3-L1 preadipocytes treated with CPPs, we examined the effect of CPP (Light) on GPDH activity, a rate-limiting enzyme in TG synthesis. As shown in Fig. 8, GPDH activity was significantly reduced, depending on the concentration of CPP (Light).

(Page 18, Line 338 to Page19, Line 342)

About English grammar in this manuscript, we had English editing before submitting by Elsevier language Editing services (Date: 06-Feb-2021, Serial number: LEEX-12443-8FF6610781E7).

Thank you very much for your suggestion, again.

Decision Letter 1

Juan J Loor

19 Feb 2021

Carob pod polyphenols suppress the differentiation of adipocytes through posttranscriptional regulation of C/EBPß

PONE-D-20-38421R1

Dear Dr. Kojima-Yuasa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Juan J Loor

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors:

All the confusion about the figures etc is now resolved.

On line 257, epididymal is mispelled as apididymal

The Scheme ! is helpful as it indicates how adipogenesis/diff can start but then lipogenesis and fat synthesis can be inhibited long term

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Juan J Loor

25 Feb 2021

PONE-D-20-38421R1

Carob pod polyphenols suppress the differentiation of adipocytes through posttranscriptional regulation of C/EBPß

Dear Dr. Kojima-Yuasa:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Juan J Loor

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES